Compare Liberty Media Corporation Series C Liberty Formula One Common Stock (FWONK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Media Corporation Series C Liberty Formula One Common Stock vs TG Therapeutics Inc — how do they compare? Liberty Media Corporation Series C Liberty Formula One Common Stock trades at $90.85 (market cap $22.59B), while TG Therapeutics Inc trades at $54.13 (market cap $8.32B). The key difference: Liberty Media Corporation Series C Liberty Formula One Common Stock is far larger — about 2.7× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Liberty Media Corporation Series C Liberty Formula One Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Media Corporation Series C Liberty Formula One Common Stock for 0 Days and TG Therapeutics Inc for 16 Days on average.
| FWONK | TGTX | |
|---|---|---|
Market Cap | $22.59B | $8.32B |
Volume | 2,257,903 | 1,285,303 |
Sector | Media | Health |
52-Week High | $106.66 | $59.06 |
52-Week Low | $81.42 | $26.94 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $26.05B | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $54.34, down 1.68% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth, with 2025 revenue at $616.29 million and net income of $447.18 million, though recent quarterly EPS results missed expectations. Analyst sentiment is overwhelmingly positive, with 11 buy ratings and a consensus price target of $80.50, while recent news highlights Briumvi's market share gains and potential acquisition interest.
The outlook for TGTX is favorable, driven by Briumvi's expanding multiple sclerosis market share and raised 2026 revenue guidance to $950 million. Key risks include ongoing earnings misses, a high EV/EBITDA ratio of 61.15, and a shareholder litigation investigation. Upside potential remains if the company meets future earnings targets and sustains its growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Liberty Media Corporation Series C Liberty Formula One Common Stock
Liberty Media Corporation's Series C Liberty Formula One common stock is a tracking stock reflecting the economic performance of the Formula One Group, which holds Liberty Media's interests in Formula 1 racing, MotoGP, and related minority investments.
Read more on FWONK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
